Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE versus GRAFAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE versus GRAFAPEX.
AMLODIPINE MALEATE; BENAZEPRIL HYDROCHLORIDE vs GRAFAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation and reduced aldosterone secretion.
GRAFAPEX is a monoclonal antibody that binds to and inhibits the activity of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
Initial: 2.5-5 mg amlodipine / 10-20 mg benazepril orally once daily, titrated to 10/40 mg once daily based on response.
10-20 mg orally once daily, maximum 40 mg per day.
None Documented
None Documented
Amlodipine: 30-50 h (terminal), allowing once-daily dosing; benazeprilat: 10-11 h (terminal), effective for 24 h.
Terminal elimination half-life: 12 hours (range 10-14 hours); clinical context: dosing interval recommended every 24 hours to maintain therapeutic levels
Renal: Amlodipine 10% unchanged, benazeprilat (active metabolite) 50-60% in urine; biliary/fecal: amlodipine 20-25% as metabolites, benazeprilat 10-20% in feces.
Renal: 60% as unchanged drug; biliary/fecal: 30%; minor metabolism: 10%
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor